Filana Therapeutics (FLNA) Cash from Operations (2010 - 2026)

Filana Therapeutics has reported Cash from Operations for 17 years, with the latest figure at -$3.8 million in Q2 2026.

• On a quarterly basis, Cash from Operations rose 22.78% year-over-year to -$3.8 million in Q2 2026; TTM through Jun 2026 was -$28.7 million, a 70.02% increase from a year earlier, with the FY2025 full-year figure at -$32.3 million, up 72.38% from the prior year.
• Cash from Operations was -$3.8 million for Q2 2026 at Filana Therapeutics, up from -$8.9 million in the prior quarter.
• The five-year high for Cash from Operations was -$3.8 million in Q2 2026, with the low at -$61.2 million in Q4 2024.
• Average Cash from Operations over 5 years is -$17.9 million, with a median of -$18.3 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations plunged 920.38% in 2022, then soared 84.0% in 2025.
• Over 5 years, Cash from Operations stood at -$21.3 million in 2022, then dropped by 4.67% to -$22.3 million in 2023, then sank by 174.37% to -$61.2 million in 2024, then jumped by 84.0% to -$9.8 million in 2025, then jumped by 60.87% to -$3.8 million in 2026.
• The last three Cash from Operations figures came in at -$3.8 million (Q2 2026), -$8.9 million (Q1 2026), and -$9.8 million (Q4 2025), per Business Quant data.